Izidore S. Lossos M.D.
University of Miami, USA
Dr. Izidore Lossos is Professor of Medicine and the Lymphoma Section Chief and Director of Lymphoma Program at Sylvester. He holds a Sylvester endowed chair at the NCI designated Sylvester Comprehensive Cancer Center. He received his medical degree from Hadassah School of Medicine, Hebrew University in Jerusalem, Israel. He completed his residency in Internal Medicine and fellowship in Hematology at Hadassah University Hospital in Jerusalem and postdoctoral fellowship with major emphasis on lymphoma at Division of Medical Oncology at Stanford University.
The focus of Dr. Lossos’s research is pathogenesis of lymphoma, identification of molecular prognostic markers and elucidation of their role in determination of response to therapy, development of new lymphoma therapies. His studies focus on diffuse large cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, primary CNS lymphoma, lymphomas of the eye and other lymphoma subtypes. His research involves basic research at the bench and translation of these findings to clinical trials. He participated in multiple clinical trials as a PI or co-PI. He has authored multiple reviews, commentaries and book chapters as well as more than 290 peer-reviewed articles in such journals as New England Journal of Medicine, Blood, Proceedings of the National Academy of Sciences USA, Nature, Cell, Nature Communications, Cancer Cell, Cancer Discovery, EMBO, Journal of Clinical Investigations, Journal of Clinical Oncology, Leukemia, Journal of Immunology, Cancer and others.
He is a recipient of the 2007- Celgene Young Investigator Award for Achievements in Clinical Hematology and the 2012 and 2020 – Sylvester Comprehensive Cancer Center Outstanding Cancer Research Award and 2020 Schally Research Award in Internal Medicine. Since 2004 and till 2020 he is recognized as an America’ Top Doctor by the A Castle Connolly Guide and in 2011-2016 was recognized as Top Doctor by US News and World Report. He serves on an Advisory board of Lymphoma Foundation.